NCT03529084View on ClinicalTrials.gov

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

July 24, 2018

Primary Completion Date

August 13, 2020

Study Completion Date

June 3, 2024

Conditions

Carcinoma, Non-small Cell Lung

Interventions

DRUG

EFG816

It will be administered orally daily.

DRUG

erlotinib or gefitinib

"Investigator's choice between erlotinib or gefitinib. These will be locally sourced.~Erlotinib will be administered orally daily. Gefitinib will be administered orally daily."